Casma is developing a new way to do targeted degradation. Many important disease targets go beyond the capacity of the ubiquitin-proteasome pathway. The PHLYT™ technology reprograms autophagy to generate autophagosomes around these disease targets resulting in degradation. This is Degradation 2.0.
We have amassed a world-class autophagy drug discovery team that is working and learning together. By leveraging our deep understanding of autophagy and dynamics, we established the PHLYT™ platform to expand targeted degradation in ways previously unimagined.
In-house validation has identified definitive autophagy targets that can be drugged with chemistry to form the foundation of PHLYT™. Degradation 2.0 is modular because this autophagy-targeting chemistry can be used to develop specific degraders for rare and common diseases.
Heterobifunctional chemistry has been developed to facilitate the recruitment of autophagy regulators to disease targets leading to autophagosome biogenesis around the target. We have demonstrated that this approach has the capacity to degrade several disease targets in a robust way.
Our team has the leading autophagy industry experts, world-class R&D capabilities, and a broad network of academic pioneers working on autophagy and proteostasis.
Our deep expertise in autophagy, disease processes, and chemical biology has enabled the discovery of autophagy proteins that can degrade multiple disease targets.
Our autophagy small-molecule ligand-discovery engine enables the development of PHLYT™ degraders. We own the ligands to make Degradation 2.0 a reality.
Knowing where and how to deploy the PHLYT™ technology is critical for successful therapeutic development. We understand the molecular features of disease targets that place them in the sweet-spot for PHLYT™-mediated degradation.
For general questions, media inquiries, or to learn more about collaborations and partnerships, click below.
Get in touchLearn what autophagy is, how it works, and why it matters.
Explore the science